ASCO in Action

ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.

To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.

Tune in to the ASCO in Action podcast series for analysis and commentary on cancer policy and practice issues. The podcast is available through iTunes or Google Play.

September 24, 2021

New research powered by CancerLinQ Discovery® de-identified data sets that is being presented at the 2021 ASCO® Quality Care Symposium (QCS) identified factors that predict the likelihood of short-term mortality for patients with metastatic breast cancer; highlighted important demographic and clinical differences between patients with breast cancer typically considered to be candidates for clinical trials and those seen in routine clinical practice; and characterized the use of telehealth for end-of-life cancer care during the pandemic.

September 22, 2021

On September 22, 2021, the Food and Drug Administration approved ruxolitinib (Jakafi, Incyte Corp.) for chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.

September 22, 2021

In comments to the Centers for Medicare & Medicaid Services (CMS), the Association for Clinical Oncology (ASCO) expressed significant concerns that several provisions in the 2022 Hospital Outpatient Prospective Payment System (HOPPS) proposed rule have the potential to undermine access to cancer care for Medicare beneficiaries. ASCO does, however, support some updates CMS has proposed for calendar year 2022.

September 21, 2021

On September 20, 2021, the Food and Drug Administration granted accelerated approval to tisotumab vedotin-tftv (Tivdak, Seagen Inc.), a tissue factor-directed antibody and microtubule inhibitor conjugate, for adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. 

September 17, 2021

On September 17, 2021, the Food and Drug Administration approved cabozantinib (Cabometyx, Exelixis, Inc.) for adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are ineligible or refractory to radioactive iodine. 

September 15, 2021

On September 15, 2021, the Food and Drug Administration granted accelerated approval to mobocertinib (Exkivity, Takeda Pharmaceuticals, Inc.) for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

September 15, 2021

​On September 14, 2021, the Food and Drug Administration granted accelerated approval to zanubrutinib (Brukinsa, BeiGene) for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.

September 14, 2021

On September 9, HHS released a report titled, Comprehensive Plan for Addressing High Drug Prices: A Report in Response to the Executive Order on Competition in the American Economy.

September 14, 2021

The Association for Clinical Oncology (ASCO) commented on provisions in the 2022 Medicare Physician Fee Schedule (MPFS) and Quality Payment Program (QPP) proposed rule that would impact cancer care for Medicare beneficiaries. The letter also offers perspective on CMS’ four-stage plan to transition CMS’ quality measurement enterprise to being fully digital by 2025 and how the agency can improve data collection and measurement to help advance health equity in the Medicare program.

September 14, 2021

On September 9, 2021, the Centers for Medicare & Medicaid Services posted new information on reprocessing claims for outpatient clinic visit services provided at excepted off-campus provider-based departments.

September 14, 2021

On September 10, 2021, the Administration announced that the U.S. Department of Health and Human Services (HHS), through the Health Resources and Services Administration (HRSA), is making $25.5 billion in new funding available for health care providers affected by the COVID-19 pandemic.

September 14, 2021

This summer, members of the Association for Clinical Oncology (ASCO) continued to push forward oncology-focused advocacy priorities by meeting with their Member of Congress or congressional staff during the congressional recess, or district work period.

September 13, 2021

The Association for Clinical Oncology (the Association) launched the ASCO Patient-Centered Cancer Care Certification, a new pilot that certifies outpatient oncology group practices and health systems that meet a single set of comprehensive, expert-backed standards for patient-centered care delivery. The pilot is based on recently published oncology medical home standards (OMH) from the American Society of Clinical Oncology (an affiliate of the Association) and the Community Oncology Alliance (COA).

September 2, 2021

The American Society of Clinical Oncology (ASCO) has a list of resources and information to support cancer care providers and patients affected by natural disasters such as Hurricane Ida.

September 1, 2021

On August 31, 2021, the Food and Drug Administration approved zanubrutinib (Brukinsa, BeiGene) for adult patients with Waldenström’s macroglobulinemia (WM).

Pages